- Home
- TERN vs EBS Comparison
TERN vs EBS Comparison
Compare TERN & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- EBS
- Stock Information
- Founded
- TERN 2017
- EBS 1998
- Country
- TERN United States
- EBS United States
- Employees
- TERN N/A
- EBS 900
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- TERN Health Care
- EBS Health Care
- Exchange
- TERN Nasdaq
- EBS Nasdaq
- Market Cap
- TERN 321.4M
- EBS 353.9M
- IPO Year
- TERN 2021
- EBS 2006
- Fundamental
- Price
- TERN $3.80
- EBS $6.39
- Analyst Decision
- TERN Buy
- EBS Strong Buy
- Analyst Count
- TERN 5
- EBS 3
- Target Price
- TERN $15.63
- EBS $14.33
- AVG Volume (30 Days)
- TERN 932.0K
- EBS 1.3M
- Earning Date
- TERN 08-04-2025
- EBS 08-05-2025
- Dividend Yield
- TERN N/A
- EBS N/A
- EPS Growth
- TERN N/A
- EBS N/A
- EPS
- TERN N/A
- EBS N/A
- Revenue
- TERN N/A
- EBS $965,400,000.00
- Revenue This Year
- TERN N/A
- EBS N/A
- Revenue Next Year
- TERN N/A
- EBS $18.88
- P/E Ratio
- TERN N/A
- EBS N/A
- Revenue Growth
- TERN N/A
- EBS N/A
- 52 Week Low
- TERN $1.87
- EBS $4.02
- 52 Week High
- TERN $11.40
- EBS $15.10
- Technical
- Relative Strength Index (RSI)
- TERN 61.74
- EBS 60.32
- Support Level
- TERN $3.66
- EBS $6.53
- Resistance Level
- TERN $4.30
- EBS $6.98
- Average True Range (ATR)
- TERN 0.31
- EBS 0.35
- MACD
- TERN -0.01
- EBS 0.01
- Stochastic Oscillator
- TERN 59.28
- EBS 84.04
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.